Nov 2023: Ngaphansi kweProjekthi Yokuvuselela, uhlelo lwe-Oncology Centre of Excellence (OCE) okuhloswe ngalo ukubuyekeza imininingwane yokulebula emithini emidala ye-oncology ukuze kuqinisekiswe ukuthi ulwazi lubalulekile ngokomtholampilo futhi luhambisana nesikhathi ngokwesayensi, iFood and Drug Administration (FDA) igunyaze ukulebula okubuyekeziwe kwe-temozolomide ( Temodar, Merck). Ngaphansi kwalolu hlelo lokuhlola, lona umuthi wesibili ukuthi ilebula yawo ibuyekezwe. I-Capecitabine (Xeloda) kwaba imithi yokuqala egunyazwe ngaphansi kwe-Project Renewal.
Ngemizamo ehlanganyelwe yokuvuselelwa kweProjekthi, ososayensi abasakhula kanye nongoti be-oncology bangaphandle bahlaziya izincwadi ezishicilelwe ukuze bathole ulwazi mathupha ekukhetheni, ekulungiseni nasekuhlolweni kwedatha yokubuyekezwa kwe-FDA ezimele. Umgomo Wokuvuselelwa Kwephrojekthi uwukugcina ukulebula kwakamuva kakhulu kwemithi ye-oncology emidala, evame ukunikezwa kuyilapho kukhulisa ulwazi lomphakathi lokulebula izidakamizwa njengomthombo wolwazi futhi kunikeze ukuvuleka kwezidingo zobufakazi ze-FDA kanye nenqubo yokuhlola.
I-Temozolomide manje isivunyelwe kulezi zinkomba ezintsha nezibuyekeziwe ezilandelayo:
- ukwelashwa kwe-adjuvant kwabantu abadala abane-anaplastic astrocytoma esanda kutholakala.
- ukwelashwa kwabantu abadala abane-refractory anaplastic astrocytoma.
Inkomba eyodwa evunyelwe ye-temozolomide isafana:
- ukwelashwa kwabantu abadala abane-glioblastoma esanda kutholakala, kanye ne-radiotherapy bese kuba njengokwelashwa kwesondlo.
Izibuyekezo zokulebula ezengeziwe zifaka:
- Umuthi wemithamo uyabuyekezwa futhi ubuyekezelwe i-glioblastoma esanda kutholwa kanye ne-refractory anaplastic astrocytoma.
- Kumaphilisi e-Temodar, ulwazi ngezingozi zokuchayeka kumaphilisi avuliwe lwengezwa ngaphansi kokuthi Izexwayiso Nezinyathelo Zokuqaphela.
- Ingxenye Yolwazi Lokwelulekwa Kwesiguli kanye nedokhumenti Yolwazi Lwesiguli ziyabuyekezwa futhi zibuyekezwe.
